The Mayo Clinic - Phoenix
Welcome,         Profile    Billing    Logout  
 4 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bryce, Alan
RECOVER, NCT04470544: Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19

Completed
2
100
US
Camostat Mesilate, Foipan, Standard of Care
Alan Bryce
Severe Acute Respiratory Syndrome
12/21
01/22
NCT05730712: Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Recruiting
2
25
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, Enzalutamide, ASP9785, MDV3100, Xtandi, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Questionnaire Administration
Mayo Clinic
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
10/25
10/25
NCT05689021: CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Recruiting
2
30
US
Abiraterone Acetate/Niraparib, Abiraterone Acetate and Niraparib Tosylate Monohydrate, Abiraterone Acetate/Niraparib Tosylate Monohydrate, Akeega, CJNJ-67652000, Niraparib and Abiraterone Acetate, Niraparib Tosylate Monohydrate and Abiraterone Acetate, Niraparib Tosylate Monohydrate/Abiraterone Acetate, Niraparib/Abiraterone Acetate, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone
Mayo Clinic
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC V8
09/25
09/25
CASCARA, NCT03934840: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Active, not recruiting
2
22
US
Cabazitaxel, Carboplatin, Abiraterone, Prednisone
Masonic Cancer Center, University of Minnesota
Prostate Cancer
06/23
05/25
Butler, Kristina
NCT05804370: Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

Recruiting
3
170
US
Gleolan
NX Development Corp
Ovarian Cancer
01/26
05/26
NCT05051722: Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Recruiting
2
2640
US
Tampon Collection, Vaginal Fluid, Blood Collection
Mayo Clinic
Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
12/25
06/26
NCT02020707: Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Completed
1
43
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Laboratory Biomarker Analysis, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Pharmacological Study
Mayo Clinic, National Cancer Institute (NCI)
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, Cervical Carcinosarcoma, Cervical Squamous Cell Carcinoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Squamous Cell Carcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Female Reproductive System Neoplasm, Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Epithelial Tumor, Malignant Ovarian Mucinous Tumor, Malignant Peritoneal Neoplasm, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Unresectable Melanoma, Uterine Corpus Carcinosarcoma
07/24
07/24
NCT06365905: Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia with an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients with Post-Menopausal Bleeding

Recruiting
N/A
300
US
Non-Interventional Study
Mayo Clinic
Endometrial Carcinoma
06/27
06/27
Aguilar, Isabel
AFEDIN, NCT05781178: Analysis of the Aetiological Factors of Malnutrition

Completed
N/A
271
Europe
Oral nutritional supplement rich in omega-3 and olive oil polyphenols, Physical activity
Endocrinology and Clinical Nutrition Research Center, Spain, Adventia Pharma
Disease-related Malnutrition, Inflammation
05/24
09/24

Download Options